Suppr超能文献

基于 FIT 的结直肠癌筛查中性别特异性截止值:更高的依从性和相等的阳性率。

Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.

机构信息

1 Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

2 Regional Cancer Centre, Stockholm-Gotland, Sweden.

出版信息

J Med Screen. 2019 Jun;26(2):92-97. doi: 10.1177/0969141318804843. Epub 2018 Oct 18.

Abstract

OBJECTIVE

Using quantitative Faecal Immunochemical Test (FIT) in colorectal cancer screening enables adjustment of the cut-off for a positive test. As men have higher stool blood levels and higher prevalence of colorectal neoplasia, different cut-off levels can be chosen for men and women. We evaluated participation and positivity rates switching from guaiac-based faecal occult blood test (gFOBT) (Hemoccult®) to FIT (OC-Sensor), using gender-specific cut-offs.

METHODS

The colorectal cancer screening programme of Stockholm-Gotland, Sweden, started in 2008 and invited individuals aged 60-69 to biennial testing using gFOBT. From 1 October 2015 the test was switched to FIT, with positivity cut-offs of 40 (200) and 80 (400) µg Hb/g (ng/mL) faeces for women and men, respectively. The first year was evaluated for compliance and positivity, number of reminders and incorrect/inadequate tests, compared with gFOBT in the preceding 12-month period.

RESULTS

There were 127,030 and 87,269 individuals invited to screening with gFOBT and FIT, respectively. The change of test increased overall participation by 11.9% (95% confidence interval 11.5%-12.3%) from 56.5% to 68.4% ( p < 0.001). The increase was larger in men (14.3%) than women (9.7%), and in those aged 60-64 (14.2%) than those aged 65-69 (8.7%). The positivity rate was 2.6% in women and 2.5% in men. There was a lower rate of reminders and incorrect/inadequate tests with FIT.

CONCLUSIONS

Within a well-organised colorectal cancer screening programme, changing the test from gFOBT to FIT markedly increased participation, especially among men, and in the younger age group. With a lower cut-off in women than men, the positivity rate was similar.

摘要

目的

在结直肠癌筛查中使用定量粪便免疫化学检测(FIT)可以调整阳性检测的截止值。由于男性粪便中血液水平较高,且结直肠肿瘤的患病率较高,因此可以为男性和女性选择不同的截止值。我们评估了使用基于愈创木脂的粪便潜血检测(gFOBT)(Hemoccult®)转换为 FIT(OC-Sensor)时,使用性别特异性截止值时的参与率和阳性率。

方法

瑞典斯德哥尔摩-哥德堡的结直肠癌筛查计划于 2008 年启动,邀请 60-69 岁的个体每两年接受一次 gFOBT 检测。从 2015 年 10 月 1 日起,将检测方法更改为 FIT,女性和男性粪便中血红蛋白的阳性截止值分别为 40(200)和 80(400)μg Hb/g(ng/mL)。与之前 12 个月的 gFOBT 相比,评估了第一年的依从性和阳性率、提醒次数以及不正确/不充分的检测。

结果

分别有 127030 人和 87269 人被邀请参加 gFOBT 和 FIT 筛查。从 56.5%增加到 68.4%(p<0.001),总体参与率增加了 11.9%(95%置信区间 11.5%-12.3%)。男性(14.3%)的增长大于女性(9.7%),60-64 岁年龄组(14.2%)大于 65-69 岁年龄组(8.7%)。女性的阳性率为 2.6%,男性为 2.5%。FIT 的提醒次数和不正确/不充分检测的比例较低。

结论

在组织良好的结直肠癌筛查计划中,将检测方法从 gFOBT 更改为 FIT 可大大提高参与率,尤其是在男性和年轻人群中。由于女性的截止值低于男性,因此阳性率相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验